Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guy Pratt

Showing results (81-90 of 134) with videos related to

Pageof 14
Sort By:
British Journal of Haematology|May 5, 2022
A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosisSriram Ravichandran, Shameem Mahmood, Brenden Wisniowski, et al.
Hepatology (Baltimore, Md.)|April 18, 2012
Recruitment mechanisms of primary and malignant B cells to the human liverShishir Shetty, Tony Bruns, Christopher J Weston, et al.
British Journal of Haematology|June 25, 2008
Pathogenic ATM mutations occur rarely in a subset of multiple myeloma patientsBelinda Austen, Giancarlo Barone, Anne Reiman, et al.
British Journal of Haematology|July 30, 2015
Time to redefine MyelomaGuy Pratt, Stella Bowcock, Andrew Chantry, et al.
Blood Advances|September 12, 2025
mTOR activity and metabolic reprogramming of CD8+ T cells is impaired under hypoxia and within the multiple myeloma bone marrowTaylor Fulton-Ward, Nancy Gudgeon, Isaac Thirlwell, et al.
Blood|January 30, 2008
The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic targetSaman Hewamana, Suhair Alghazal, Thet Thet Lin, et al.
British Journal of Haematology|March 10, 2023
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trialSian E Faustini, Andrew Hall, Sarah Brown, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 13, 2026
Translation approaches to support systemic anti-cancer therapy consent for individuals with limited English proficiencyStephen P Hibbs, Rumman Nizam, Ubaid Tanzim, et al.
Oncogene|February 20, 2003
Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanismJames A L Fenton, Guy Pratt, Andy C Rawstron, et al.
American Journal of Hematology|April 29, 2016
Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemiaHelen Marie Parry, Sarah Damery, Christopher Hudson, et al.
Pageof 14

Showing results (81-90 of 134) with videos related to

Sort By:
Pageof 14
British Journal of Haematology|May 5, 2022
A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosisSriram Ravichandran, Shameem Mahmood, Brenden Wisniowski, et al.
Hepatology (Baltimore, Md.)|April 18, 2012
Recruitment mechanisms of primary and malignant B cells to the human liverShishir Shetty, Tony Bruns, Christopher J Weston, et al.
British Journal of Haematology|June 25, 2008
Pathogenic ATM mutations occur rarely in a subset of multiple myeloma patientsBelinda Austen, Giancarlo Barone, Anne Reiman, et al.
British Journal of Haematology|July 30, 2015
Time to redefine MyelomaGuy Pratt, Stella Bowcock, Andrew Chantry, et al.
Blood Advances|September 12, 2025
mTOR activity and metabolic reprogramming of CD8+ T cells is impaired under hypoxia and within the multiple myeloma bone marrowTaylor Fulton-Ward, Nancy Gudgeon, Isaac Thirlwell, et al.
Blood|January 30, 2008
The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic targetSaman Hewamana, Suhair Alghazal, Thet Thet Lin, et al.
British Journal of Haematology|March 10, 2023
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trialSian E Faustini, Andrew Hall, Sarah Brown, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 13, 2026
Translation approaches to support systemic anti-cancer therapy consent for individuals with limited English proficiencyStephen P Hibbs, Rumman Nizam, Ubaid Tanzim, et al.
Oncogene|February 20, 2003
Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanismJames A L Fenton, Guy Pratt, Andy C Rawstron, et al.
American Journal of Hematology|April 29, 2016
Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemiaHelen Marie Parry, Sarah Damery, Christopher Hudson, et al.
Pageof 14